Proteogenomic Characterization of Tumor Tissues and Preclinical Models with High Precision

总结 自CPTAC 2以来的12年中，JHU蛋白质组表征中心（JHU/PCC） 一再证明了上级技术创新和强大的数据生成能力， 在CPTAC的核心使命的成功中发挥了关键作用， 通过大规模蛋白质组分析的应用， 技术适用于不同的癌症类型。对于这个项目，我们的目标是生成准确的，可重复的， 使用优化和标准化的高灵敏度、定量和多重蛋白质组学分析， 吞吐量技术。我们将利用我们已建立的中心基础设施， 我们在临床癌症蛋白基因组学发现中的成功， 来自费城儿童医院的磷酸化，代表自己和儿童 脑肿瘤组织联盟（CBTTC），儿童脑肿瘤网络，该中心的一部分 生物医学数据驱动发现（Data Driven Discovery in Biomedicine at CHOP）我们将确定独特的功能， 是蛋白质所固有的，如磷酸化，已包括在我们目前的PCC中。 了解癌发生的分子网络对于促进 精确的癌症医学和制定成功的战略，以降低癌症死亡率。

Summary During the last 12 years of since CPTAC2, the JHU Proteome Characterization Center (JHU/PCC) has repeatedly demonstrated superior technological innovation and robust data generation that have played critical roles in the success of CPTAC's core mission of accelerating the understanding of the molecular basis of cancer through the application of large-scale proteome analysis technologies to different cancer types. For this project, we aim to generate accurate, reproducible, sensitive, quantitative, and multiplexed proteomic analysis using optimized and standardized high- throughput technologies. We will leverage our established Center infrastructure and capitalize on our success in clinical cancer proteogenomic discoveries to characterize proteins and protein phosphorylation from The Children's Hospital of Philadelphia, on behalf of itself and the Children Brain Tumor Tissue Consortium (CBTTC), the Children's Brain Tumor Network, a part of the Center for Data Driven Discovery in Biomedicine at CHOP ) (CBTN). We will identify unique features that are inherent to proteins such as phosphorylation that have been included in our current PCC. Understanding the molecular network in carcinogenesis is essential for the advancement of precision cancer medicine and development of a successful strategy to reduce cancer mortality.